At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- YL201 (drug), Atezolizumab (drug)
- How long the study runs
- Study runs about 35 months (dates as stated)
- About the drug or intervention
- YL201 — drug: YL201 intravenous infusion will be administered on Day 1 of each 21-day cycle. · Atezolizumab — drug: Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 118
- Started
- 2026-03-31
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for thoracic neoplasms, lung diseases, small cell lung carcinoma
- • Phase1/Phase2 - 118 participants
- • This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with thoracic neoplasms, lung diseases, small cell lung carcinoma
Where?
- • Edinburgh - Site 2203
- • London - Site 2201
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must NOT have had:
- ✗ systemic anti-cancer
- ✗ treatment targeting B7H3 or topoisomerase I inhibitor
Who cannot take part
- ✗No prior systemic anti-cancer treatment for ES-SCLC
- ✗No prior treatment targeting B7H3 or topoisomerase I inhibitor
- ✗No clinically active brain metastases or spinal cord compression
- ✗No current or history of interstitial lung disease (ILD)/ pneumonitis
- ✗No clinically significant cardiovascular disease (eg, New York Heart Association class II to IV congestive heart...
See the full criteria
Where Is This Study? (2 UK sites)
Site 2203
Edinburgh EH4 2XU, United Kingdom
Site 2201
London W12 0HS, United Kingdom
How to Get in Touch
MediLink Study Team
Sponsor contactCONTACT